B ackground: Nowadays PPI present cornerstone in the medical therapy of bleeding peptic ulcer. Controlled pantoprazole data in peptic ulcer bleeding are few. Aim: To compare the effect of intravenous (iv) pantoprazole (PPI) with iv ranitidine (H2RA) for bleeding peptic ulcers after endoscopic therapy. Methods: After endoscopic haemostasis, 122 patients were randomized to PPI 80 mg + 8mg/h or H2RA 50 mg + 13mg/h, both for 72 h and to continue with oral equivalent dose of these medicaments. Patients underwent second-look endoscopy on day 3 or earlier, if clinically indicated. The primary endpoint measure was rebleeding before discharge and <14 days of enrollment. Secondary endpoint measures included number of surgeries performed, volume of blood transfusion, mortality rate and hospital stay. All data were statistically analyzed and a value of 0.05 or less was considered to indicate statistical significance. Results: In the group who were treated with PPI, re-bleeding rate was evidenced in 5 patients (8.33%) and in the groups who were treated with H2RA, re-bleeding rate was found in 9 patients (14.5%) with RR 0.27 and CI 0.12-0.60 and P< 0.05. The volume of transfused blood was lower in the group treated with PPI compared to the group treated with H2RA (930 ml vs. 1540 ml and P< 0.05). In this study there was not statistically significant difference in the hospital stay 15.00 vs. 17.80% (9 vs. 11 patients and P> 0.05), the need for surgical intervention 5.00 vs. 6.45% (3 vs. 4 patients and P= 1.00 ) and the mortality rate 1.66 vs. 3.22% (1 vs. 2 patients and P> 0.05).Conclusion: A high-dose pantoprazole infusion is more effective than a ranitidine infusion for prevention of re-bleeding after endoscopic epinephrine injection in patients with peptic ulcers and active bleeding or non-bleeding visible vessels (P<0.05). In all bleeding peptic ulcer patients is needed to make the eradication of H. pylori infection with the aim to prevent re-bleeding in long term.
INTRODUCTION
Acute non-variceal upper gastrointestinal bleeding is a common cause of hospitalization, and it is associated with mortality rates as high as 6-14% (1, 2, 3) .
Most ulcers cease bleeding spontaneously as a result of intrinsic haemostatic mechanisms, but in one fifth of cases these mechanisms may fail, and the bleeding continues (4) .
The risk for recurrent bleeding is increased in patients with major bleeding and endoscopic evidence of a peptic ulcer with recent stigmata. In such cases, endoscopic hemostasis can control bleeding and reduce the re-bleeding rate, morbidity and even mortality (5, 6) .
The endoscopic epinephrine injection is one of the most common therapies for bleeding peptic ulcer. Administration of PPI after successful injected therapy with epinephrine is of great importance, while, its administration is associated with high gastric pH. Clot formation over arteries is pH dependent: a gastric pH above 6 is thought to be critical for platelet aggregation (7) . We hypothesized that administration Med Arh. 2012 Aug; 66(4): 236-239 • ORIGINAL pApeR
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AIM
To evaluate the efficacy of the PPI treatment in comparison with H 2 RA after endoscopic injection of epinephrine in patients with bleeding peptic ulcer.
MeTHODS

Design
In this prospective, double-blind, randomized compared study were included 122 patients with active bleeding or non-bleeding visible vessels who achieved hemostasis after endoscopic injection of epinephrine. All patients or their legal representatives provided written informed consent for participation in the trial, according to Good Clinical Practice guidelines.
Patients
Consecutive patients who presented with overt signs of upper gastrointestinal bleeding (i.e., melena or hematemesis with or without hypotension) to the Service of Gastroenterohepatology on UCCK, Prishtina, and partially in UHC, Clinic of Gastrohepathology in Skopje, were evaluated by admitting residents for inclusion in the trial. Patients with hypotensive shock (systolic blood pressure < 90 mmHg or pulse > 110 bpm) were initially resuscitated and were then considered for entering the trial if their condition had been stabilized. Patients with continued shock despite initial volume resuscitation underwent urgent endoscopy and were excluded.
Patients were also excluded, if they had oesophageal varices, portal hypertension, Child's C liver cirrhosis or concomitant disease that made inclusion inappropriate (e.g. terminal disease, malignancy of GI tract, uremia, with a known allergy to PPI and those who were using aspirin regularly for cardiovascular protection, GI bleeding from other sources), if they had a bleeding tendency (platelet count <50x10 9 /l, serum prothrombin <30% of normal, or use of anticoagulants).
For patients who had bleeding ulcers associated with ingestion of nonsteroidal anti-inflammatory drugs, the drugs were discontinued. Patients who had life-threatening bleeding and were using warfarin or had bleeding from an overdose of warfarin were given vitamin K or fresh-frozen plasma. Patients for whom anticoagulation was considered necessary underwent heparin therapy until the bleeding was stabilized.
Bleeding was considered to have recurred if any of the following occurred: vomiting of fresh blood, hypotensive shock (defined as a systolic blood pressure < 90 mmHg or a pulse >110 beats per minute) with melena after stabilization, or a decrease in hemoglobin level of more than 2g per deciliter and a decrease in the hematocrit of more than 6% within 24 hours after a transfusion, resulting in a hemoglobin level of 10g per deciliter or less. Patients who were judged to have recurrent bleeding underwent urgent endoscopy by endoscopists on duty. Recurrent bleeding was confirmed if the ulcer was actively bleeding (spurting or oozing hemorrhage) or if there was fresh blood in the stomach and vessel at the ulcer base. Clots overlying ulcers were lifted, and the base of the ulcer was examined. Endoscopic therapy was repeated on the bleeding artery. Surgical intervention was deemed to be warranted if the bleeding could not be controlled by endoscopic methods or if there was a second recurrence of bleeding.
Eradication of H. pylori for all patients in this study was done with a 1-week course of 20 mg pantoprazole twice daily, 500 mg clarithromycin twice daily and 1g of amoxicillin twice daily, was confirmed with the use of a rapid urease test and histologic analysis during follow-up endoscopy at 8 weeks or serologically proven after nearly 8 months.
Medical data, including the characteristics of patients' ulcers and endosopic findings were collected on study entry. Patients were randomly allocated to one of two regimens after endoscopic hemostasis with video-endoscope OLYMPUS GIF type Q145 and injection using 1: 10000 adrenaline (range 6-15 ml): the first group (pantoprazole group) with 60 patients were treated with PPI, 40 mg pantoprazole infusion every 6 hours for 3 days followed with 80 mg per oral dose of pantoprazole (2x40 mg) and the second group (ranitidine group) with 62 patients were treated with 50 mg ranitidine infusion every 8 hours for 3 days followed with 300 mg per oral dose of ranitidine (2x150 mg), for 8 weeks, for both groups. All the patients were followed for survey characteristics during 14 days after the first examination. At endocopy, gastroduodenal ulcers with spurting hemorrhage, oozing hemorrhage, or nonbleeding visible vessels (defined as protuberant discolorations) were injected with epinephrine (dilution 1:10.000). Aliqutos of ephinephrine (0.5 to 1 ml) were injected around the bleeding vessel with the use of a 23-gauge sclerotherapy needle until bleeding had completely ceased. Coaptive thermocoagulation was then applied to vessels with use of a 3.2-mm heater probe (model CD-10Z, Olympus). Hemostasis was considered to have been established if bleeding had stopped and if formerly bleeding vessels were flattened or cavitated. Clots covering ulcer craters were elevated by means of irrigation through a heater probe for up to 5 minutes or "cheese-wiring" with a mini-snare, and underlying vessels, if present, were treated. Preinjection with diluted epinephrine at the pedicle of the clot was permeitted. Antral-biopsy specimens were obtained and subjected to a rapid urease test (HUT test, Astra Zeneca) and histologic examination to determine whether Helicobacter pylori infection was present, and partially with serologic test. If patient's vital signs were poor or if their hemoglobin level reached <90g/l, a blood transfusion was given. All patients underwent endoscopy 72h after enrollment. If there were signs of hemorrhage or blood clot at the ulcer base on endoscopy patients were discharged. An emergency endoscopy was performed in patients with suspected re-bleeding. Re-bleeding was defined as a fresh blood clot or bleeding from the ulcer base, and was treated with heater probe thermocoagulation. An emergency operation was performed if re-bleeding recurred after two attempts of thermocoagulation.
The primary endpoint measure was re-bleeding before discharge and <14 days of enrollment. Secondary endpoint measures included number of surgeries performed, volume of blood transfusion, mortality rate and hospital stay.
Med Arh. 2012 Aug; 66(4): 236-239 • ORIGINAL pApeR
The efficacy of PPI after endoscopic hemostasis in Patients with Bleeding Peptic Ulcer and role of helicobacter Pylori
Patients were followed-up for a period of one year with the aim of evidencing eventual re-bleeding, in eradicated and non-eradicated group.
All data were statistically analyzed and a value of 0.05 or less was considered to indicate statistical significance.
ReSULTS
In total, during a 15-month period between January 2007 and May 2008, 122 patients were included in the study: 60 were given the regimen that included 40 mg pantoprazole every 6h, 62 were given the regimen that included 50 mg ranitidine every 8h. It was continued with oral dose, with consecutive antisecretor drugs for a period of 8 weeks.
The demographics, clinical and endoscopic variables are presented in the following Table 1 , who showed that these variables were not significantly different for both investigated groups (Pantoprazole and Ranitidine group).
In the group who were treated with PPI, re-bleeding rate was evidenced in 5 patients (8.33%) and in the groups who were treated with H 2 RA, re-bleeding rate was evidenced in 9 patients (14.5%) with RR 0.27 and CI 0.12-0.60 and P< 0.05.
The volume of transfused blood was lower in the group treated with PPI compared to the group treated with H 2 RA (930 ml vs. 1540 ml and P< 0.05).
In this study there was not statistically significant difference in the hospital stay 15.00% vs. 17.80% (9 vs. 11 patients and P> 0.05), the need for surgical intervention 5.00% vs. 6.45% (3 vs. 4 patients and P= 1.00 ) and the mortality rate 1.66% vs. 3.22% (1 vs. 2 patients and P> 0.05).
From the 122 patients who were included in this study, all treated with triple therapy for eradication of infection with H. pylori, in 108 patients was achieved eradication of H. pylori (88.5%) and in 14 patients or 11.5% was not achieved eradication of H. pylori. Status for H. pylori infection was proved with serology after 8 months from the eradication. In the non-eradicated group with triple therapy, 12 from 14 patients or 85.71% had re-bleeding episodes during the one year of followup time. In two patients associated cofactor included the use of aspirin due to cardiac co-morbidity and were treated with PPI comedication In the eradication group (108 patients), only 10 patients or 9.26% had re-bleeding episodes during the same time of follow-up. The re-bleeding rate between eradicated and noneradicated group (9.26% vs. 85.71%) were with significant difference (P<0.01). (Table 1 , Graph 2).
DISCUSSION
The study provides evidence to support the notion that the rate of recurrent bleeding from peptic ulcer after endoscopic hemostasis is pH dependent. The maintenance of an intragastric pH of 6 is thought to be critical for clot stability, thrombocyts aggregation, inactivation of pepsin and finally, ulcer hemostasis.
A f ter succe s sf u l hemost a si s achieved by means of adrenaline injection during endoscopy, the administration of antisecretors in cases of bleeding from peptical ulcer is of great im- From the 122 patients who were included in this study, all treated with triple therapy for eradication of infection with H. pylori, in 108 patients was achieved eradication of H. pylori (88.5%) and in 14 patients or 11.5% was not achieved eradication of H. pylori. Status for H. pylori infection was proved with serology after 8 months from the eradication. In the non-eradicated group with triple therapy, 12 from 14 patients or 85.71% had re-bleeding episodes during the one year of follow-up time. In two patients associated cofactor included the use of aspirin due to cardiac co-morbidity and were treated with PPI co-medication In the eradication group (108 patients), only 10 patients or 9.26% had re-bleeding episodes during the same time of follow-up. The re-bleeding rate between eradicated and noneradicated group (9.26% vs. 85.71%) were with significant difference (P<0.01). (Tab. 1, Graf. 2).
Graph 1. The relationship of the efficacity between PPI and H2RA
In the group who were treated with PPI, re-bleeding rate was evidenced in 5 patients (8.33%) and in the groups who were treated with H 2 RA, re-bleeding rate was evidenced in 9 patients (14.5%) with RR 0.27 and CI 0.12-0.60 and P< 0.05. From the 122 patients who were included in this study, all treated with triple therapy for eradication of infection with H. pylori, in 108 patients was achieved eradication of H. pylori (88.5%) and in 14 patients or 11.5% was not achieved eradication of H. pylori. Status for H. pylori infection was proved with serology after 8 months from the eradication. In the non-eradicated group with triple therapy, 12 from 14 patients or 85.71% had re-bleeding episodes during the one year of follow-up time. In two patients associated cofactor included the use of aspirin due to cardiac co-morbidity and were treated with PPI co-medication In the eradication group (108 patients), only 10 patients or 9.26% had re-bleeding episodes during the same time of follow-up. The re-bleeding rate between eradicated and noneradicated group (9.26% vs. 85.71%) were with significant difference (P<0.01). (Tab. 1, Graf. 2).
The efficacy of PPI after endoscopic hemostasis in Patients with Bleeding Peptic Ulcer and role of helicobacter Pylori portance in order to attain a convenient pH which would induct the coagulation stability and stop the bleeding (1). The above-described doses of ranitidine were earlier utilized in our clinic for this aim. But, due to PPI emerging, various contemporary references shunt ranitidine while favoring PPI (2) . In fact, the aim of the present research comprised of comparing the effects of these two groups of medicaments. The results of our study indicated that the effect of PPI, compared to that of H 2 RA in preventing of recurrent bleeding from peptic ulcer after the efficient hemostasis reached by means of adrenaline, is of a statistically significant difference (8.33 % vs. 14.5 % and P<0.05).
Studies from other authors have revealed similar results. In a study conducted by Gisbert JP. et. al. (6) , it was found that the recurrent bleeding from peptical ulcer was significantly lower in the group treated with PPI than in the group treated with H 2 RA (6.7 % vs. 13.4 % OR 0.4, 95 %, CI 0.27 to 0.59 ). The results of our study showed that the volume of transfused blood was lower in the group treated with PPI than in the group treated with H 2 RA (930 ml vs. 1540 ml and P< 0.05). In our study, the hospitalization duration, the necessity for surgical intervention and mortality did not manifest statistically significant differences in both groups. Martin JE et al. and Leontiadis et al. (12, 13) showed that PPI decreased the need for blood transfusions in patients with bleeding peptic ulcer. In this study, in contrast to our study, the need for surgery, time of hospitalization and mortality were decreased. The reason for this is due to the fact that most of our patients did not show up on time in our Department, which is in the early phase of bleeding from the peptic ulcer, which in turn influenced the hospitalization duration, the higher necessity for surgical interventions and higher mortality. Different authors from their 27 studies, conducted in over 2500 patients with upper digestive bleeding, refer that there is no difference of statistical significance between treatment with H 2 RA (21 %) and treatment with placebo (23 %) (7) . Actually only one of the 27 patients included in the study was found to benefit from therapy with H 2 RA in preventing recurrent bleeding from peptic ulcer. A number of meta-analysis (8) do not support the role of ranitidine in preventing bleeding recurrence from duodenal ulcer and point out that patients with gastric ulcer can have a slightly higher benefit. On the other hand, according to many studies (9), treatment with PPI showed to have significantly reduced recurrent bleeding from peptic ulcer (6.7 %) for the 30-day observation period, compared to the group treated with placebo in which the degree of recurrent bleeding for this period was 22.5 %, but there was no difference of statistical significance concerning the hospitalization duration, mortality and the need for surgical intervention, even though these were evidently lower in the group treated with PPI. Fried R. et al. (10) also refer to the PPI advantage over H 2 RA in patients diagnosed with Forrest Ia, Ib, IIa and IIb after hemostasis therapy with adrenaline injection. Barkun AN et. al. (11) mention distinct advantages in preventing recurrent bleeding from peptic ulcer in the group treated with PPI (5.9 %) compared to the group not treated with PPI (22.9 %). The dimension of costs and that of effectiveness also speak in favor of PPI administration since the costs associated with recurrent bleeding, prolonged hospitalization and the necessity for surgical intervention can be unforeseen (3, 5).
CONCLUSION
A high-dose pantoprazole infusion is more effective than a ranitidine infusion for prevention of re-bleeding after endoscopic epinephrine injection in patients with peptic ulcers and active bleeding or non-bleeding visible vessels (P<0.05).
After one year follow-up, non-eradicated patients with H. pylori infection had often re-bleeding episodes in comparison with eradicated patients for H. pylori (P<0.01).
Thus, eradication of infection with H. pylori is very important factor for the prevention of recurrent bleeding in patients with peptic ulcer. Moreover, in all patients with bleeding peptic ulcer, after successful endoscopic and medical treatment it is needed to do eradication of infection with H. pylori.
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DISCUSSION
The study provides evidence to support the notion that the rate of recurrent bleeding from peptic ulcer after endoscopic hemostasis is pH dependent. The maintenance of an intragastric pH of 6 is thought to be critical for clot stability, thrombocyts aggregation, inactivation of pepsin and finally, ulcer hemostasis. After successful hemostasis achieved by means of adrenaline injection during endoscopy, the administration of antisecretors in cases of bleeding from peptical ulcer is of great importance in order to attain a convenient pH which would induct the coagulation stability and stop the bleeding (1). The above-described doses of ranitidine were earlier utilized in our clinic for this aim. But, due to PPI emerging, various contemporary references shunt ranitidine while favoring PPI (2) . In fact, the aim of the present research comprised of comparing the effects of these two groups of medicaments. The results of our study indicated that the effect of PPI, compared to that of H2RA in preventing of recurrent bleeding from peptic ulcer after the efficient hemostasis reached by means of adrenaline, is of a statistically significant difference (8.33 % vs. 14.5 % and P<0.05).
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